“`html
Jyong Biotech Ltd., a Taiwan-based biotechnology company, has priced its initial public offering (IPO) at $7.50 per share, aiming to raise approximately $20 million for drug development. The IPO includes 2,666,667 ordinary shares and is set to list on the Nasdaq Global Market under the ticker “MENS,” with trading commencing on June 17, 2025, pending standard conditions. The offering is expected to close on June 18, 2025.
The proceeds from the IPO are designated for funding various clinical trials, with approximately 40% allocated to Phase III trials of the drug candidate MCS-2. Joseph Stone Capital, LLC is the sole underwriter for the offering, with a possibility for the underwriters to purchase an additional 400,000 shares to cover over-allotments.
“`
